2-Methoxyestrone is a metabolite of estrone, a primary estrogen hormone in humans. It is formed through the methylation of estrone at the 2-position, resulting in the addition of a methoxy (-OCH3) group.
This chemical modification alters the structure and properties of estrone, giving rise to this metabolite with distinct biochemical characteristics.
As a biomarker, 2-Methoxyestrone offers insights into estrogen metabolism, hormone balance, and disease pathophysiology. Understanding the significance of 2-Methoxyestrone in health and disease has sparked interest in its utilization for diagnostic, prognostic, and therapeutic purposes.
2-Methoxyestrone is a metabolically significant 17-oxo steroid characterized by the addition of a methoxy (-OCH3) group at the 2-position of the estrone molecule. This chemical modification alters the structure and properties of estrone, resulting in a metabolite with distinct biochemical activity and characteristics.
Produced through the action of catechol-O-methyltransferase on 2-hydroxyestrone, 2-methoxyestrone can further undergo transformations to form sulfated or glucuronidated derivatives via enzyme-mediated reactions.
Notably, it exhibits low affinity for estrogen receptors, indicating minimal estrogenic activity compared to other related compounds. However, it may have roles in non-receptor mediated pathways in mammalian physiology.
Estrogens play critical roles in various physiological processes including regulating reproductive function and the menstrual cycle, bone health, cardiovascular function, and cognitive function and mood.
Additionally, estrogen signaling influences lipid metabolism, glucose homeostasis, and immune function.
It also affects skin elasticity, hair growth, body weight, and fat distribution, while contributing to sexual health by enhancing vaginal wall thickness and lubrication. Additionally, estrogen is crucial for breast development during puberty and preparing for lactation.
Estrone (E1) is one of the three main estrogens produced in the human body, alongside estradiol (E2) and estriol (E3). It becomes the predominant form of estrogen in postmenopausal women.
Estrone is primarily synthesized in adipose tissue through the aromatization of androstenedione, an androgen produced by the adrenal glands and the ovaries. This process becomes especially important after menopause when ovarian estrogen production declines.
The actions of estrogens in the body are influenced by the specific structure of each estrogen molecule, the type of estrogen receptor it binds to, and the cellular context.
Estrogens exert their effects by binding to estrogen receptors, which are part of the nuclear hormone receptor superfamily. These receptors exist mainly in two forms, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), each encoded by different genes and varying structurally, particularly in their ligand-binding domains.
This difference in structure affects their affinity for various ligands; for instance, some estrogens and phytoestrogens preferentially bind ERβ, whereas others have a higher affinity for ERα.
Once bound to an estrogen, the receptor undergoes a conformational change, allowing it to dissociate from chaperone proteins and move into the nucleus where it binds to DNA at sites known as estrogen-response elements.
This binding can either activate or repress the transcription of target genes depending on the presence of coactivators or corepressors in the complex.
The distribution of estrogen receptors varies across different tissues, which partly explains the tissue-specific effects of estrogen. For example, ERα is predominantly found in reproductive tissues like the endometrium, while ERβ is more common in non-reproductive tissues such as bone and brain.
This selective expression and the unique interaction of estrogens with their receptors underpin the diverse physiological roles of estrogens, from reproductive functions to their roles in bone density and cardiovascular health.
2-Methoxyestrone seems to have less affinity for estrogen receptors than other forms of estrogen or its metabolites. For this reason, it is associated with a lower risk of certain cancers.
2-Methoxyestrone and Breast Cancer [8.]
The study measuring estrogen metabolites (EMs) found that higher levels of 2-methoxyestrone were associated with a reduced risk of postmenopausal breast cancer.
Women in the highest quartile of 2-methoxyestrone concentration had significantly lower odds of developing breast cancer compared to those in the lowest quartile, with odds ratios indicating a protective effect.
This suggests that increased metabolism of estrogens along the 2-pathway, leading to higher levels of 2-methoxyestrone, could potentially be beneficial in reducing breast cancer risk among postmenopausal women.
Further research is needed to confirm these findings and to explore the potential mechanisms by which 2-methoxyestrone may exert its protective effects, although this is a promising indication that supporting proper estrogen metabolism may correlate with reduced disease risk.
2-Methoxyestrone and Obesity [15.]
In a study involving 1835 postmenopausal women from the Women’s Health Initiative Observational Study, researchers investigated the association of body mass index (BMI) and other anthropometric measures with circulating levels of estrogen metabolites, including 2-methoxyestrone.
The findings revealed that higher current BMI was significantly associated with elevated levels of parent estrogens and other metabolites among non-users of menopausal hormone therapy (MHT). Specifically, after accounting for estradiol levels, an inverse association was noted between BMI and 2-methoxyestrone concentrations.
Among MHT users, while BMI did not affect parent estrogen levels, it was inversely associated with methylated catechols, including 2-methoxyestrone.
This study underscores the complexity of estrogen metabolism in relation to body weight and its potential implications for hormone-related cancer risks, highlighting that higher BMI in postmenopausal women is linked to specific changes in estrogen metabolism, such as reduced levels of 2-methoxyestrone.
Urine samples are commonly used for 2-Methoxyestrone testing.
Estrogen metabolites can be excreted in the urine, making it a reliable method for testing estrogen detoxification and comparing ratios of estrogen metabolites. Urine testing specifically assesses phase I estrogen detoxification, and it can also be used to assess phase II methylation detoxification.
Urine collection can be easier and less stressful for patients compared to blood draws, as samples can be collected at home without the need for a clinical setting. Additionally, urinary levels can reflect longer-term hormone exposure rather than the transient levels often seen in blood, as it reflects detoxification patterns (rather than providing snapshots of levels in the bloodstream).
It is important to consult with the lab company providing testing for 2-methoxyestrone levels. For reference, one lab provides the following reference range for urine 2-methoxyestrone levels: [17.]
For cycling women in the luteal phase: 2.5-6.5 ng/mg
For postmenopausal women not supplementing with hormones: 0.3-1.4 ng/mg
Hormones never act alone, and their effects are nuanced. Optimal levels of 2-methoxyestrone in urine tests vary depending on individual health conditions, gender, and age. 2-Methoxyestrone is still considered the preferred estrogen detoxification pathway.
One recommendation is that 60-80% of a woman's circulating estrogen utilize the 2-OH pathway; that 13-30% utilizes the 16-OH pathway; and that the remaining 7.5-11% utilizes the 4-OH pathway. [17.]
Health professionals often recommend that women remain within the reference range of 2.5-6.5 ng/mg in urine samples for cycling women, or 0.3-1.4 ng/mg in urine samples for postmenopausal women. However, a professional's recommendation will be affected by many factors including the patient’s overall health, detoxification capacity, personal and family health history, time of life, diet and lifestyle, medications, and other factors.
Regular monitoring through urinary tests is essential to ensure that the metabolite levels are within a safe range, thereby reducing the potential for DNA damage and promoting better hormonal balance and overall health.
In postmenopausal women receiving hormone replacement therapy, elevated levels of 2-methoxyestrone may indicate an excessive amount of hormone supplementation which may be causing unwanted overstimulation of estrogen-sensitive tissue at the breasts and endometrium.
These women should have their dosages assessed by a healthcare professional, and estrogen detoxification support may be considered.
Premenopausal women with elevated levels of 2-methoxyestrone should be assessed by a healthcare professional, including a comprehensive assessment of male and female sex hormones, as well as considering adrenal and thyroid hormone levels. Additionally, estrogen detoxification support may be considered.
Premenopausal women, or women supplementing with estrogen who complain of estrogen excess symptoms, should be assessed for estrogen and estrogen metabolite levels.
See below for more information on natural methods to promote hormone balance.
Typically, declining levels of estrogen and its metabolites are seen postmenopausally. Testing of estrogen metabolites may be recommended for women complaining of menopausal symptoms.
Additionally, postmenopausal women with a family or personal history of osteoporosis or low bone mineral density should consider testing their estrogen and estrogen metabolite levels.
Several other biomarkers are associated with estrogen metabolism and activity. Other estrogen metabolites including 16-hydroxyestrone (16-OH-E1) and 4-hydroxyestrone (4-OH-E1), as well as estrone (E1), estradiol (E2), and estriol (E3) levels should be considered.
2-OH estrone is a direct precursor in the metabolic pathway that leads to 2-methoxyestrone.
Evaluating both metabolites provides a more comprehensive view of estrogen metabolism, particularly in the 2-OH pathway, and helps in understanding the balance between estrogen metabolites that may influence cancer risk and other hormone-related conditions.
16-Hydroxyestrone (16-OH E1) is a metabolite of estrone, one of the three main naturally occurring estrogens in the human body.
Unlike some other estrogen metabolites, 16-OH E1 exhibits relatively strong estrogenic activities. It binds to estrogen receptors, potentially influencing estrogen-responsive gene expression and cellular functions.
This metabolite has been associated with various physiological effects and is implicated in different health conditions, including increased risks for certain types of cancers due to its potent estrogenic properties.
4-OH estrone is another metabolite of estrone with strong estrogenic properties and potential carcinogenic effects.
Specifically, 4-OH estrone is known for its potential to form quinones that can directly damage DNA and generate reactive oxygen species, increasing the risk of mutagenesis.
Measuring 4-OH estrone alongside 16-OH estrone and 2-OH estrone can help assess the overall estrogenic and carcinogenic potential within the body.
Estrone is a weaker estrogen compared to estradiol but is prevalent in postmenopausal women and can be converted back to estradiol.
Testing for estrone is important for understanding the overall estrogenic activity, especially in postmenopausal women who are at increased risk for estrogen-sensitive cancers.
Estradiol is the most potent estrogen and has significant implications for bone density, reproductive health, and cardiovascular health. Monitoring estradiol levels is essential for assessing reproductive health and menopausal status, and for managing hormone replacement therapy effectively.
Estriol is a weak estrogen predominantly produced during pregnancy. Outside of pregnancy, its levels are very low, but it has been suggested to have protective effects against breast cancer.
Testing for estriol, especially in non-pregnant states, might provide additional insights into estrogenic activity and potential protective mechanisms against estrogen-related pathologies.
It is always essential to work with a qualified healthcare professional in any case of hormone imbalance. The following diet and lifestyle measures have been shown to naturally promote healthy hormone balance:
Dietary Fiber Increase: consuming more fiber helps bind estrogen in the digestive tract, promoting its excretion and reducing reabsorption. [9.]
Interestingly, one study of 240 women also showed a correlation between increased fiber intake and anovulation, possibly due to lower estrogen levels. [9.]
Cruciferous Vegetables: foods like broccoli, cauliflower, and Brussels sprouts contain indole-3-carbinol, which aids in detoxifying excessive estrogen and optimizing hormone balance. [3.]
Regular Exercise: physical activity can help balance hormones by improving metabolism and reducing fat, which is significant since body fat can produce and store estrogen. [19.]
Probiotics and Gut Health: a healthy gut flora supports proper digestion and detoxification processes, including the breakdown, elimination and balance of hormones like estrogen. [13.]
Limit Alcohol and Caffeine: reducing intake of substances that can impair liver function helps ensure the liver effectively processes and removes excess hormones. [7., 18.]
Stress Management: stress may have an impact on estrogen levels and metabolism; techniques such as yoga, meditation, or even simple breathing exercises can reduce cortisol levels and help maintain a healthy hormonal balance. [2.]
Click here to explore testing options and order testing for 2-Methoxyestrone levels.
[1.] 004564: Estrone | Labcorp. www.labcorp.com. https://www.labcorp.com/tests/004564/estrone
[2.] Assad S, Khan HH, Ghazanfar H, Khan ZH, Mansoor S, Rahman MA, Khan GH, Zafar B, Tariq U, Malik SA. Role of Sex Hormone Levels and Psychological Stress in the Pathogenesis of Autoimmune Diseases. Cureus. 2017 Jun 5;9(6):e1315. doi: 10.7759/cureus.1315. PMID: 28690949; PMCID: PMC5498122.
[3.] Auborn KJ, Fan S, Rosen EM, et al. Indole-3-Carbinol Is a Negative Regulator of Estrogen. The Journal of Nutrition. 2003;133(7):2470S2475S. doi:https://doi.org/10.1093/jn/133.7.2470s
[4.] Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, Blandino G, Gallucci M, Lauria R, Malorni L, Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res. 2009 Oct 8;28(1):135. doi: 10.1186/1756-9966-28-135. PMID: 19814782; PMCID: PMC2766371.
[5.] Diaz-Ruano AB, Martinez-Alarcon N, Perán M, Benabdellah K, Garcia-Martinez MLÁ, Preda O, Ramirez-Tortosa C, Gonzalez-Hernandez A, Marchal JA, Picon-Ruiz M. Estradiol and Estrone Have Different Biological Functions to Induce NF-κB-Driven Inflammation, EMT and Stemness in ER+ Cancer Cells. Int J Mol Sci. 2023 Jan 7;24(2):1221. doi: 10.3390/ijms24021221. PMID: 36674737; PMCID: PMC9865376.
[6.] Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2029-35. doi: 10.1158/1055-9965.EPI-08-0262. PMID: 18708395; PMCID: PMC2562592.
[7.] Emanuele MA, Wezeman F, Emanuele NV. Alcohol's effects on female reproductive function. Alcohol Res Health. 2002;26(4):274-81. PMID: 12875037; PMCID: PMC6676690.
[8.] Falk, R.T., Brinton, L.A., Dorgan, J.F. et al. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res 15, R34 (2013). https://doi.org/10.1186/bcr3416
[9.] Gaskins AJ, Mumford SL, Zhang C, et al. Effect of daily fiber intake on reproductive function: the BioCycle Study. The American Journal of Clinical Nutrition. 2009;90(4):1061-1069. doi:https://doi.org/10.3945/ajcn.2009.27990
[10.] Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and Actions of Estrogens. New England Journal of Medicine. 2002;346(5):340-352. doi:https://doi.org/10.1056/nejmra000471
[11.] Human Metabolome Database: Showing metabocard for 2-Methoxyestrone (HMDB0000010). hmdb.ca. Accessed April 30, 2024. https://hmdb.ca/metabolites/HMDB0000010
[12.] Lira-Silva E, del Valle Mondragón L, Pérez-Torres I, et al. Possible implication of estrogenic compounds on heart disease in menopausal women. Biomedicine & Pharmacotherapy. 2023;162:114649. doi:https://doi.org/10.1016/j.biopha.2023.114649
[13.] Maeng LY, Beumer A. Never fear, the gut bacteria are here: Estrogen and gut microbiome-brain axis interactions in fear extinction. International Journal of Psychophysiology. 2023;189:66-75. doi:https://doi.org/10.1016/j.ijpsycho.2023.05.350
[14.] National Center for Biotechnology Information. PubChem Compound Summary for CID 440624, 2-Methoxyestrone. https://pubchem.ncbi.nlm.nih.gov/compound/2-Methoxyestrone. Accessed Apr. 30, 2024.
[15.] Oh, H., Coburn, S.B., Matthews, C.E. et al. Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women’s Health Initiative Observational Study. Breast Cancer Res 19, 28 (2017). https://doi.org/10.1186/s13058-017-0810-0
[16.] Obi N, Vrieling A, Heinz J, Chang-Claude J. Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16α-hydroxyestrone ratio predictive for breast cancer? Int J Womens Health. 2011 Feb 8;3:37-51. doi: 10.2147/IJWH.S7595. PMID: 21339936; PMCID: PMC3039007.
[17.] RUPA DUTCH Complete M+F Sample Report.pdf. Google Docs. Accessed April 27, 2024. https://dutchtest.com/wp-content/uploads/2024/05/1.5.1-Sample-Report_DUTCH-Complete_Female.pdf
[18.] Sisti JS, Hankinson SE, Caporaso NE, Gu F, Tamimi RM, Rosner B, Xu X, Ziegler R, Eliassen AH. Caffeine, coffee, and tea intake and urinary estrogens and estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1174-83. doi: 10.1158/1055-9965.EPI-15-0246. Epub 2015 Jun 10. PMID: 26063478; PMCID: PMC4526325.
[19.] Smith AJ, Phipps WR, Thomas W, Schmitz KH, Kurzer MS. The effects of aerobic exercise on estrogen metabolism in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):756-64. doi: 10.1158/1055-9965.EPI-12-1325. PMID: 23652373; PMCID: PMC3648856.
[20.] Stanczyk FZ. The 2-/16α-Hydroxylated Estrogen Ratio-Breast Cancer Risk Hypothesis: Insufficient Evidence for its Support. Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology. 2020;201:105685-105685. doi:https://doi.org/10.1016/j.jsbmb.2020.105685
[21.] The Journal of Clinical Endocrinology & Metabolism. What Does Estrogen Do? The Journal of Clinical Endocrinology & Metabolism. 2014;99(4):31A32A. doi:https://doi.org/10.1210/jc.2014-v99i4-31a
[22.] Xu S, Sun J, Zhang Y, Ji J, Sun X. Opposite estrogen effects of estrone and 2-hydroxyestrone on MCF-7 sensitivity to the cytotoxic action of cell growth, oxidative stress and inflammation activity. Ecotoxicology and Environmental Safety. 2021;209:111754. doi:https://doi.org/10.1016/j.ecoenv.2020.111754